Ana Slipicevic

One Carbon Therapeutics

Ana Slipicevic, Ph.D. is an executive in the biotechnology and clinical research field, with two decades of experience in therapeutic oncology. She has a track record leading translational research and drug development from preclinical discovery through early-phase clinical trials. Currently serving as CEO of One-carbon Therapeutics AB, Ana has successfully delivered regulatory approvals for first-in-human (FIH) studies across multiple regions and built a lean, high-performing R&D organization. Her previous roles include PI of in vivo pharmacology at Medivir AB and Translational Research Director at Oncopeptides AB, where she directed biomarker strategy, clinical trial support, and the establishment of laboratory facilities. Ana’s holds a Ph.D. in medical sciences from the University of Oslo, and leadership and economy education from University of Oslo and London school of Economics.